First PhIII data show once-weekly omarigliptin as good as daily Januvia
This article was originally published in Scrip
Executive Summary
Merck & Co's first Phase III data from its once-weekly DPP-4 inhibitor omarigliptin showed it works as well as the company's successful once-daily diabetes drug Januvia (sitagliptin). Merck is working towards a first filing in Japan by year-end.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.